Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer
1996

Comparing Two Doses of Megestrol Acetate for Cancer-Related Appetite Loss

Sample size: 122 publication Evidence: moderate

Author Information

Author(s): V Gebbia, A Testa, N Gebbia

Primary Institution: Service of Chemotherapy, Policlinico, University of Palermo, Italy

Hypothesis

Does a higher dose of megestrol acetate lead to better appetite stimulation and weight gain in patients with cancer-related anorexia-cachexia syndrome?

Conclusion

The study confirms the safety and effectiveness of megestrol acetate in managing anorexia-cachexia syndrome in advanced cancer patients, with no significant difference between the two doses tested.

Supporting Evidence

  • 55% of patients on 160 mg reported increased appetite after 30 days.
  • 68% of patients on 320 mg reported increased appetite after 30 days.
  • 31% of patients on 160 mg showed weight gain after 30 days.
  • 45% of patients on 320 mg showed weight gain after 30 days.
  • Overall analysis showed no significant difference in appetite or weight gain between the two doses.

Takeaway

This study looked at two doses of a medicine called megestrol acetate to see if it helps cancer patients eat better and gain weight. Both doses helped, but the higher dose didn't work any better than the lower one.

Methodology

Patients were randomly assigned to receive either 160 mg or 320 mg of megestrol acetate daily, and their appetite and weight were monitored over 30 days.

Limitations

The study did not find statistically significant differences in appetite or weight gain between the two doses, and the sample may not represent all cancer patients.

Participant Demographics

Patients had advanced cancer, were aged 18-75, and had a performance status of Karnofsky Index >50.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication